Tatjana Mitchell serves as Chief Financial Officer at Evolus Inc., a leading aesthetics company renowned for its innovative neurotoxin Jeuveau. With over 20 years of experience in finance within the pharmaceutical and biotechnology sectors, Tatjana began her career at Deloitte & Touche, where she honed her expertise in audit and advisory services for life sciences clients. She later advanced to senior finance roles at Allergan and AbbVie, managing multimillion-dollar budgets, SEC reporting, and strategic mergers during periods of rapid growth and regulatory scrutiny. Tatjana's notable achievements include spearheading the financial restructuring of a mid-cap biotech firm that resulted in a 40% increase in shareholder value within two years, as well as leading AbbVie's international expansion into emerging markets. Recognized as a CFA charterholder and recipient of the Women in Finance Leadership Award in 2022, she brings a proven track record of driving profitability and operational efficiency. Her strategic foresight was instrumental in navigating complex IPO processes and venture funding rounds. At Evolus, Tatjana oversees all financial operations, including capital allocation, risk management, and investor relations, positioning the company for sustained growth in the competitive aesthetics market. Under her leadership, Evolus has achieved record revenue growth and strengthened its balance sheet, enabling accelerated R&D investments and global market penetration. Tatjana is a passionate advocate for diversity in STEM, serving on the board of the Biotechnology Innovation Organization's finance committee.